These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 18648643)

  • 1. Effective gene therapy in a mouse model of prion diseases.
    Toupet K; Compan V; Crozet C; Mourton-Gilles C; Mestre-Francés N; Ibos F; Corbeau P; Verdier JM; Perrier V
    PLoS One; 2008 Jul; 3(7):e2773. PubMed ID: 18648643
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of PrPSc formation by lentiviral gene transfer of PrP containing dominant negative mutations.
    Crozet C; Lin YL; Mettling C; Mourton-Gilles C; Corbeau P; Lehmann S; Perrier V
    J Cell Sci; 2004 Nov; 117(Pt 23):5591-7. PubMed ID: 15494372
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Single treatment with RNAi against prion protein rescues early neuronal dysfunction and prolongs survival in mice with prion disease.
    White MD; Farmer M; Mirabile I; Brandner S; Collinge J; Mallucci GR
    Proc Natl Acad Sci U S A; 2008 Jul; 105(29):10238-43. PubMed ID: 18632556
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lentivector-mediated RNAi efficiently suppresses prion protein and prolongs survival of scrapie-infected mice.
    Pfeifer A; Eigenbrod S; Al-Khadra S; Hofmann A; Mitteregger G; Moser M; Bertsch U; Kretzschmar H
    J Clin Invest; 2006 Dec; 116(12):3204-10. PubMed ID: 17143329
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gene and cell therapy for prion diseases.
    Relaño-Ginés A; Gabelle A; Lehmann S; Milhavet O; Crozet C
    Infect Disord Drug Targets; 2009 Feb; 9(1):58-68. PubMed ID: 19200016
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Convection-enhanced delivery of AAV2-PrPshRNA in prion-infected mice.
    Ahn M; Bajsarowicz K; Oehler A; Lemus A; Bankiewicz K; DeArmond SJ
    PLoS One; 2014; 9(5):e98496. PubMed ID: 24866748
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PrPC knockdown by liposome-siRNA-peptide complexes (LSPCs) prolongs survival and normal behavior of prion-infected mice immunotolerant to treatment.
    Bender H; Noyes N; Annis JL; Hitpas A; Mollnow L; Croak K; Kane S; Wagner K; Dow S; Zabel M
    PLoS One; 2019; 14(7):e0219995. PubMed ID: 31329627
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Developmental influence of the cellular prion protein on the gene expression profile in mouse hippocampus.
    Benvegnù S; Roncaglia P; Agostini F; Casalone C; Corona C; Gustincich S; Legname G
    Physiol Genomics; 2011 Jun; 43(12):711-25. PubMed ID: 21406608
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prion protein transgenes and the neuropathology in prion diseases.
    DeArmond SJ; Prusiner SB
    Brain Pathol; 1995 Jan; 5(1):77-89. PubMed ID: 7767493
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RNAi: a novel strategy for the treatment of prion diseases.
    Kong Q
    J Clin Invest; 2006 Dec; 116(12):3101-3. PubMed ID: 17143323
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transmission of prion disease.
    Blättler T
    APMIS; 2002 Jan; 110(1):71-8. PubMed ID: 12064258
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral Prion Neuroinvasion Occurs Independently of PrP
    Marshall A; Bradford BM; Clarke AR; Manson JC; Mabbott NA
    J Virol; 2018 Oct; 92(19):. PubMed ID: 30021891
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiprion prophylaxis by gene transfer of a soluble prion antagonist.
    Genoud N; Ott D; Braun N; Prinz M; Schwarz P; Suter U; Trono D; Aguzzi A
    Am J Pathol; 2008 May; 172(5):1287-96. PubMed ID: 18372425
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapy in prion diseases: from molecular and cellular biology to therapeutic targets.
    Krammer C; Vorberg I; Schätzl HM; Gilch S
    Infect Disord Drug Targets; 2009 Feb; 9(1):3-14. PubMed ID: 19200010
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapy for prion diseases: Insights from the use of RNA interference.
    White MD; Mallucci GR
    Prion; 2009; 3(3):121-8. PubMed ID: 19597349
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Fluorescent Oligothiophene-Bis-Triazine ligand interacts with PrP fibrils and detects SDS-resistant oligomers in human prion diseases.
    Imberdis T; Ayrolles-Torro A; Duarte Rodrigues A; Torrent J; Alvarez-Martinez MT; Kovacs GG; Verdier JM; Robitzer M; Perrier V
    Mol Neurodegener; 2016 Jan; 11():11. PubMed ID: 26809712
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Delivery of single-chain antibodies (scFvs) directed against the 37/67 kDa laminin receptor into mice via recombinant adeno-associated viral vectors for prion disease gene therapy.
    Zuber C; Mitteregger G; Schuhmann N; Rey C; Knackmuss S; Rupprecht W; Reusch U; Pace C; Little M; Kretzschmar HA; Hallek M; Büning H; Weiss S
    J Gen Virol; 2008 Aug; 89(Pt 8):2055-2061. PubMed ID: 18632978
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antisense oligonucleotides extend survival of prion-infected mice.
    Raymond GJ; Zhao HT; Race B; Raymond LD; Williams K; Swayze EE; Graffam S; Le J; Caron T; Stathopoulos J; O'Keefe R; Lubke LL; Reidenbach AG; Kraus A; Schreiber SL; Mazur C; Cabin DE; Carroll JB; Minikel EV; Kordasiewicz H; Caughey B; Vallabh SM
    JCI Insight; 2019 Jul; 5(16):. PubMed ID: 31361599
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Subclinical prion disease induced by oral inoculation.
    Thackray AM; Klein MA; Bujdoso R
    J Virol; 2003 Jul; 77(14):7991-8. PubMed ID: 12829838
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Soluble dimeric prion protein binds PrP(Sc) in vivo and antagonizes prion disease.
    Meier P; Genoud N; Prinz M; Maissen M; Rülicke T; Zurbriggen A; Raeber AJ; Aguzzi A
    Cell; 2003 Apr; 113(1):49-60. PubMed ID: 12679034
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.